Human immune reconstruction
CD34+ HSC engraftment for studies requiring broader human lymphoid and myeloid immune-cell representation.
HUMANIZED IMMUNE MODEL
CD34+ HSC Humanized Mouse Models
The documented HSC-humanized platform engrafts human CD34+ hematopoietic stem cells into NOG-EXL mice expressing human GM-CSF and IL-3.
The platform is designed to support both lymphoid and myeloid differentiation, including granulocyte, monocyte, and macrophage lineages.
MODEL OVERVIEW
Broader human immune reconstitution for tumor-microenvironment research.
NOG-EXL HSC-humanized mice are described as supporting T-, B-, NK-, and multiple myeloid-cell compartments. The model is positioned for studying immune-cell function and interactions between infiltrating myeloid cells and tumors.
Therapeutic areaImmuno-oncology
SpeciesMouse
Host platformNOG-EXL
Typical useLymphoid, Myeloid studies
TYPICAL APPLICATIONS
What this model can support.
Tumor microenvironment
Investigate interactions between tumor tissue and infiltrating human immune-cell populations.
T-cell biology
Study effector and regulatory T-cell functions within a humanized immune context.
Myeloid biology
Assess granulocyte, monocyte, macrophage, and related myeloid-cell contributions when included in the protocol.
COMMON READOUTS
Readouts selected around the study question.
Endpoints are finalized with the selected model, species or strain, treatment design, and partner laboratory before study placement.
Immune composition
Protocol-defined T-, B-, NK-, monocyte, and other reconstructed human immune-cell populations.
Myeloid compartment
Differentiated myeloid populations and tumor-infiltration readouts where included.
T-cell function
Effector and regulatory T-cell endpoints selected for the study question.
Tumor immunity
Tumor-immune interaction and pharmacology readouts in project-specific study designs.
Donor, engraftment criteria, tumor pairing, study duration, immune-cell panels, and tissue-analysis package are confirmed during technical review.
STUDY DESIGN
Key factors aligned before execution.
- CD34+ HSC donor and source
- NOG-EXL engraftment criteria
- Required lymphoid and myeloid compartments
- Tumor model or biological context
- Study duration and dosing plan
- Immune-monitoring and tissue endpoints
Discuss Your Program
Share the compound, mechanism, development question, preferred model, and intended endpoints. We can review fit, feasibility, and the appropriate partner-laboratory route for a HSC Humanized study.
Required fields are marked with an asterisk(*).